Target Price | $57.60 |
Price | $12.81 |
Potential |
349.65%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Diffusion Pharmaceuticals Inc. 2025 .
The average Diffusion Pharmaceuticals Inc. target price is $57.60.
This is
349.65%
register free of charge
$70.00
446.45%
register free of charge
$35.00
173.22%
register free of charge
|
|
A rating was issued by 5 analysts: 5 Analysts recommend Diffusion Pharmaceuticals Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Diffusion Pharmaceuticals Inc. stock has an average upside potential 2025 of
349.65%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 7.14 | 8.66 |
21.29% | ||
EBITDA Margin | -109.38% | -173.44% |
58.56% | ||
Net Margin | -94.75% | -151.00% |
59.37% |
5 Analysts have issued a sales forecast Diffusion Pharmaceuticals Inc. 2024 . The average Diffusion Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Diffusion Pharmaceuticals Inc. EBITDA forecast 2024. The average Diffusion Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Diffusion Pharmaceuticals Inc. Analysts have issued a net profit forecast 2024. The average Diffusion Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.82 | -1.59 |
92.85% | 93.90% | |
P/E | negative | |
EV/Sales | 7.00 |
2 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast for earnings per share. The average Diffusion Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Diffusion Pharmaceuticals Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Diffusion Pharmaceuticals Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.